Levetiracetam versus placebo in childhood and adolescent autism

A double-blind placebo-controlled study

Stacey Wasserman, Rupa Iyengar, William F. Chaplin, Dryden Watner, Shulamit E. Waldoks, Evdokia Anagnostou, Latha Soorya, Eric Hollander

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

The purpose of this study was to determine the safety and efficacy of the anticonvulsant levetiracetam in the treatment of children with autism. A previous open-label study in autistic children treated with levetiracetam demonstrated effectiveness in hyperactivity, impulsivity/aggression, and mood lability. Twenty patients with autism ranging from 5 to 17 years of age were entered into a 10-week, placebo-controlled, double-blind trial of levetiracetam versus placebo. The mean maximum dosage for levetiracetam was 862.50±279.19 mg/day. We evaluated global improvement of autism with the Clinical Global Impression-Improvement (CGI-I) Scale and aggression and affective instability with the Aberrant Behavior Checklist (ABC) parent and teacher ratings. We measured repetitive behaviors using the Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS) score and impulsivity and hyperactivity with the Conners' Rating Scale-Revised: Long Version for parent and teacher. No significant difference was found between levetiracetam and placebo groups comparing the change in CGI-I (t=0.350, d.f.=13.621, P=0.765), nor on change in ABC, CY-BOCS or Conners' scales. These findings suggest that levetiracetam does not improve behavioral disturbances of autism, but are limited by the small sample size and lack of stratification of the autistic sample at baseline.

Original languageEnglish (US)
Pages (from-to)363-367
Number of pages5
JournalInternational Clinical Psychopharmacology
Volume21
Issue number6
DOIs
StatePublished - Nov 2006
Externally publishedYes

Fingerprint

etiracetam
Autistic Disorder
Placebos
Impulsive Behavior
Child Behavior
Checklist
Aggression
Anticonvulsants
Sample Size

Keywords

  • Anticonvulsants
  • Autism
  • Levetiracetam

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Levetiracetam versus placebo in childhood and adolescent autism : A double-blind placebo-controlled study. / Wasserman, Stacey; Iyengar, Rupa; Chaplin, William F.; Watner, Dryden; Waldoks, Shulamit E.; Anagnostou, Evdokia; Soorya, Latha; Hollander, Eric.

In: International Clinical Psychopharmacology, Vol. 21, No. 6, 11.2006, p. 363-367.

Research output: Contribution to journalArticle

Wasserman, Stacey ; Iyengar, Rupa ; Chaplin, William F. ; Watner, Dryden ; Waldoks, Shulamit E. ; Anagnostou, Evdokia ; Soorya, Latha ; Hollander, Eric. / Levetiracetam versus placebo in childhood and adolescent autism : A double-blind placebo-controlled study. In: International Clinical Psychopharmacology. 2006 ; Vol. 21, No. 6. pp. 363-367.
@article{c508aac02a5d4d5d805a5e7849e8032a,
title = "Levetiracetam versus placebo in childhood and adolescent autism: A double-blind placebo-controlled study",
abstract = "The purpose of this study was to determine the safety and efficacy of the anticonvulsant levetiracetam in the treatment of children with autism. A previous open-label study in autistic children treated with levetiracetam demonstrated effectiveness in hyperactivity, impulsivity/aggression, and mood lability. Twenty patients with autism ranging from 5 to 17 years of age were entered into a 10-week, placebo-controlled, double-blind trial of levetiracetam versus placebo. The mean maximum dosage for levetiracetam was 862.50±279.19 mg/day. We evaluated global improvement of autism with the Clinical Global Impression-Improvement (CGI-I) Scale and aggression and affective instability with the Aberrant Behavior Checklist (ABC) parent and teacher ratings. We measured repetitive behaviors using the Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS) score and impulsivity and hyperactivity with the Conners' Rating Scale-Revised: Long Version for parent and teacher. No significant difference was found between levetiracetam and placebo groups comparing the change in CGI-I (t=0.350, d.f.=13.621, P=0.765), nor on change in ABC, CY-BOCS or Conners' scales. These findings suggest that levetiracetam does not improve behavioral disturbances of autism, but are limited by the small sample size and lack of stratification of the autistic sample at baseline.",
keywords = "Anticonvulsants, Autism, Levetiracetam",
author = "Stacey Wasserman and Rupa Iyengar and Chaplin, {William F.} and Dryden Watner and Waldoks, {Shulamit E.} and Evdokia Anagnostou and Latha Soorya and Eric Hollander",
year = "2006",
month = "11",
doi = "10.1097/01.yic.0000224787.13782.0f",
language = "English (US)",
volume = "21",
pages = "363--367",
journal = "International Clinical Psychopharmacology",
issn = "0268-1315",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Levetiracetam versus placebo in childhood and adolescent autism

T2 - A double-blind placebo-controlled study

AU - Wasserman, Stacey

AU - Iyengar, Rupa

AU - Chaplin, William F.

AU - Watner, Dryden

AU - Waldoks, Shulamit E.

AU - Anagnostou, Evdokia

AU - Soorya, Latha

AU - Hollander, Eric

PY - 2006/11

Y1 - 2006/11

N2 - The purpose of this study was to determine the safety and efficacy of the anticonvulsant levetiracetam in the treatment of children with autism. A previous open-label study in autistic children treated with levetiracetam demonstrated effectiveness in hyperactivity, impulsivity/aggression, and mood lability. Twenty patients with autism ranging from 5 to 17 years of age were entered into a 10-week, placebo-controlled, double-blind trial of levetiracetam versus placebo. The mean maximum dosage for levetiracetam was 862.50±279.19 mg/day. We evaluated global improvement of autism with the Clinical Global Impression-Improvement (CGI-I) Scale and aggression and affective instability with the Aberrant Behavior Checklist (ABC) parent and teacher ratings. We measured repetitive behaviors using the Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS) score and impulsivity and hyperactivity with the Conners' Rating Scale-Revised: Long Version for parent and teacher. No significant difference was found between levetiracetam and placebo groups comparing the change in CGI-I (t=0.350, d.f.=13.621, P=0.765), nor on change in ABC, CY-BOCS or Conners' scales. These findings suggest that levetiracetam does not improve behavioral disturbances of autism, but are limited by the small sample size and lack of stratification of the autistic sample at baseline.

AB - The purpose of this study was to determine the safety and efficacy of the anticonvulsant levetiracetam in the treatment of children with autism. A previous open-label study in autistic children treated with levetiracetam demonstrated effectiveness in hyperactivity, impulsivity/aggression, and mood lability. Twenty patients with autism ranging from 5 to 17 years of age were entered into a 10-week, placebo-controlled, double-blind trial of levetiracetam versus placebo. The mean maximum dosage for levetiracetam was 862.50±279.19 mg/day. We evaluated global improvement of autism with the Clinical Global Impression-Improvement (CGI-I) Scale and aggression and affective instability with the Aberrant Behavior Checklist (ABC) parent and teacher ratings. We measured repetitive behaviors using the Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS) score and impulsivity and hyperactivity with the Conners' Rating Scale-Revised: Long Version for parent and teacher. No significant difference was found between levetiracetam and placebo groups comparing the change in CGI-I (t=0.350, d.f.=13.621, P=0.765), nor on change in ABC, CY-BOCS or Conners' scales. These findings suggest that levetiracetam does not improve behavioral disturbances of autism, but are limited by the small sample size and lack of stratification of the autistic sample at baseline.

KW - Anticonvulsants

KW - Autism

KW - Levetiracetam

UR - http://www.scopus.com/inward/record.url?scp=33749333337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749333337&partnerID=8YFLogxK

U2 - 10.1097/01.yic.0000224787.13782.0f

DO - 10.1097/01.yic.0000224787.13782.0f

M3 - Article

VL - 21

SP - 363

EP - 367

JO - International Clinical Psychopharmacology

JF - International Clinical Psychopharmacology

SN - 0268-1315

IS - 6

ER -